Pharmacy & Drug Pricing
Expert articles and analysis related to pharmacy & drug pricing.
AI Summary — Last 30 Days
CMS’s drug-pricing agenda under the Trump administration is moving from broad negotiation authority into operational design fights, with midsize biotechs pressing the White House and HHS to drop pending CMS pricing models while policy analysts focus on how negotiated Part B prices could be effectuated without destabilizing provider buy-and-bill economics or access to specialty therapies. For VBC stakeholders, the near-term tension is whether Medicare drug savings are captured through administrable payment reforms and formularies or shifted into utilization friction—especially as CMS’s proposed overhaul of drug prior authorization raises access, equity, and administrative-burden concerns for plans, ACOs, and specialty providers managing high-cost populations (CMS prior authorization proposal analysis; Part B drug effectuation tradeoffs). Medicaid is also becoming a test bed for targeted obesity-drug coverage, with Indiana planning limited GLP-1 coverage under the BALANCE model—signaling that states may pair expensive pharmacotherapy with population-health guardrails rather than offer broad, unmanaged access.
Related Articles
The Drug Changing Medicine
By EMANUEL SARKEES The United States is in the middle of what researchers are calling one of the most significant pharmacological developments in modern medicine. GLP-1 receptor agonists, the drug cla...
Medicaid MFN Pricing Could Save $8.6 Billion
Draft guidance released for 2028 cycle of Medicare drug price negotiations
Draft guidance released for 2028 cycle of Medicare drug price negotiations American Hospital Association
Midsize biotechs press White House to drop CMS pricing rules
A number of midsize biotech companies have met with White House and HHS officials in the last week, presenting their case for why two pending CMS pricing models could hinder their business and should ...
The price of Ozempic is a meaningless phrase
By JOHN SAMARAS Ask what Ozempic costs. The honest answer runs from $25 a month to $1,100 a month, and every number in that range is real, published, and defensible. A phraseContinue reading...
15 More Medicare Drugs Are Getting Price Cuts in 2027
15 More Medicare Drugs Are Getting Price Cuts in 2027 - Find Out If Yours Is on the List AOL.com
STAT+: FTC settles lawsuit with CVS Caremark over charges it manipulated insulin prices, impeded access
The FTC settled a lawsuit against CVS Caremark over allegations that the company artificially inflated the price of insulin and impeded access to the diabetes treatment.
CVS Caremark reaches settlement with FTC over insulin suit
Terms of the deal announced Tuesday are very similar to those the FTC reached with Express Scripts earlier this year, including requiring the PBM to stop preferring higher cost versions of drugs on st...
TrumpRx at 6 months: Has the drug-pricing experiment delivered?
TrumpRx at 6 months: Has the drug-pricing experiment delivered? Becker's Hospital Review
PBMs pitch bolder ways to rein in employer drug costs
PBMs pitch bolder ways to rein in employer drug costs Modern Healthcare